A randomized phase III trial run out of the United Kingdom has found that estradiol skin patches suppress testosterone as effectively as standard hormone injections in men with locally advanced or metastatic prostate cancer, while carrying a similar long-term cardiovascular risk profile. The Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial, coordinated by the MRC Clinical Trials Unit at University College London, is the largest head-to-head comparison of transdermal estradiol (tE2) against luteinizing hormone-releasing hormone (LHRH) agonist injections for androgen deprivation therapy (ADT). The results challenge the longstanding assumption that estrogen-based treatments expose patients to unacceptable heart risks, and they open a practical question: could a needle-free patch replace the injections that millions of prostate cancer patients currently receive?
What the PATCH Trial Tested
The trial enrolled men with locally advanced or metastatic prostate cancer and randomized them to receive either tE2 patches or LHRH agonist injections, the current default form of ADT worldwide. LHRH agonists work by shutting down the brain’s signal to produce testosterone, but they do so through a synthetic peptide that must be injected, typically every one to three months. Estradiol patches deliver the hormone through the skin and suppress testosterone through a different mechanism, one that also preserves bone density more effectively than LHRH agonists in some earlier studies. The PATCH registry confirms the trial’s phase III design, its eligibility criteria for advanced disease, and the specific intervention and comparator definitions that governed enrollment.
The trial began with a phase 2 component that established proof of concept before expanding into the larger phase 3 noninferiority design. A subsequent analysis published in the New England Journal of Medicine confirmed that the phase 2 comparison of tE2 patches with LHRH agonists focused on the primary outcomes of testosterone suppression, overall survival, and safety, setting the stage for the definitive cardiovascular findings. By demonstrating early that estradiol patches could reliably achieve castrate levels of testosterone, investigators had the justification to broaden the study and follow patients long enough to capture major adverse cardiovascular events.
Heart Risk Parity, Not Excess
The central concern about estrogen therapy for prostate cancer dates back decades. Oral estrogens, particularly diethylstilbestrol, caused serious cardiovascular and thromboembolic events in earlier trials, which effectively ended estrogen’s role in prostate cancer treatment by the 1980s. Those harms were linked to first-pass metabolism in the liver, which can upregulate clotting factors and raise the risk of heart attack, stroke, and venous thrombosis. The PATCH investigators hypothesized that delivering estradiol through the skin would bypass the liver’s first-pass metabolism and avoid the clotting cascade that made oral estrogens dangerous.
Their long-term cardiovascular outcomes analysis, published in The Lancet Oncology, reported hazard ratios for major adverse cardiac events and included thromboembolic data comparing the two arms. The PATCH programme analysis found no significant excess cardiovascular morbidity or mortality in the patch group relative to the LHRH agonist group. This is the key safety evidence supporting tE2 patches as a viable ADT alternative: the patches did not replicate the cardiovascular harm caused by oral estrogens. For clinicians who have avoided estrogen-based ADT for decades because of those historical risks, the data represents a meaningful reassurance that transdermal delivery changes the risk calculus.
The study did identify expected estrogen-related side effects such as gynecomastia and breast tenderness, which were more common in the patch arm. Conversely, some LHRH agonist-associated toxicities, including metabolic disturbances and injection-site reactions, were less prominent among patients using patches. Importantly, the cardiovascular event curves for the two groups remained closely aligned over extended follow-up, suggesting that any residual difference in heart risk is small compared with the large historical signal seen with oral estrogens.
Why a Patch Matters Beyond Convenience
Framing estradiol patches as merely a “needle-free option” understates what is at stake. LHRH agonists carry their own side-effect burden, including hot flashes, metabolic syndrome, loss of bone mineral density, sexual dysfunction, and fatigue. Patches may offer a different side-effect profile. Earlier research cited within the PATCH bibliography suggested that transdermal estradiol preserves bone density better than LHRH agonists, though the PATCH trial itself has not published a dedicated subgroup analysis on long-term bone health outcomes. That gap matters: osteoporotic fractures are a significant source of morbidity in men on prolonged ADT, and a treatment that controls cancer while protecting bones would carry real clinical weight.
There is also an access dimension that most coverage of the trial overlooks. LHRH agonist injections require clinic visits, cold-chain storage, and trained staff to administer. In rural areas, low-income settings, or health systems with limited infrastructure, those requirements create barriers. A self-applied patch that a patient changes at home could reduce missed doses and lower the logistical cost of long-term ADT. Whether that theoretical advantage translates into better real-world adherence remains unproven; the PATCH trial’s published reports, catalogued through curated collections, do not yet include detailed dosing adherence metrics comparing the two arms, and no dedicated analysis of patient-reported quality-of-life outcomes from PATCH participants has been released in full.
From the patient perspective, the choice between injections and patches is not trivial. Some men may prefer infrequent clinic visits and less frequent dosing, while others value the autonomy and flexibility of a self-applied patch. Skin irritation, patch visibility, and the need to remember regular changes are practical issues that will influence uptake. These everyday considerations will shape how widely tE2 is adopted if regulators and guideline panels ultimately endorse it as an alternative standard of care.
Where PATCH Fits in Evolving Treatment Standards
Prostate cancer treatment has changed rapidly in recent years, with androgen receptor pathway inhibitors (ARPIs) such as abiraterone, enzalutamide, and apalutamide now routinely combined with ADT for advanced disease. The STAMPEDE platform, a multi-arm, multi-stage study that has tested numerous treatment combinations, has been central to establishing these new standards. Its registry documents protocol evolution and the progressive addition of ARPI combinations to experimental arms, helping define when intensified systemic therapy improves survival over ADT alone.
The PATCH findings do not exist in isolation from this shift. If patches are equivalent to injections as the ADT backbone, then the next logical question is whether patches can serve as the foundation onto which ARPIs are layered. Updated protocol details on ARPI integration in ongoing PATCH arms have not been fully reported, and no head-to-head evidence yet shows that tE2-based regimens perform identically to LHRH-based regimens when combined with modern agents. Nonetheless, the noninferiority of testosterone suppression and the comparable cardiovascular profile create a strong biological rationale to explore such combinations in future studies.
Guideline committees will need to consider how to frame estradiol patches within existing treatment algorithms. They could be positioned as an alternative ADT option for men without contraindications to estrogen, particularly those at high risk of osteoporosis or those who face barriers to regular injection visits. Alternatively, some health systems may view patches as a second-line ADT approach for patients who cannot tolerate LHRH agonists. Ultimately, decisions will depend on regulatory review, health-economic analyses, and the degree of comfort clinicians have with revisiting estrogen-based therapy after decades of avoidance.
Data Gaps and Next Questions
Despite the strength of the cardiovascular findings, important questions remain. Long-term skeletal outcomes, including fracture rates and changes in bone mineral density, have not been fully characterized in PATCH publications. Similarly, detailed quality-of-life data comparing hot flashes, sexual function, mood, and cognitive effects between patches and injections would be highly informative but are not yet available in comprehensive form. These gaps limit the ability of clinicians to tailor ADT choices based on individual comorbidities and patient preferences.
There are also practical implementation issues. Health systems would need to develop prescribing pathways, patient education materials, and monitoring protocols specific to estradiol patches. For example, clinicians may need to monitor for breast changes more closely, address concerns about feminizing side effects, and provide clear guidance on patch placement and rotation. Digital tools such as patient portals and secure preference settings, akin to those used in online account management, could support adherence reminders and symptom reporting for patients using patches at home.
Further research will also need to address whether specific subgroups, such as men with pre-existing cardiovascular disease, diabetes, or prior thromboembolic events, derive similar net benefit from tE2 compared with LHRH agonists. The existing PATCH analysis suggests overall parity in heart risk, but more granular subgroup reporting would help clinicians personalize decisions in complex cases.
Revisiting Old Assumptions
The PATCH programme underscores how delivery route can transform the risk profile of a drug class. Estrogens were largely abandoned in prostate cancer because oral formulations increased cardiovascular events; transdermal delivery appears to have broken that link. As more clinicians engage with the detailed PATCH data, including supplementary materials accessible through bibliographic tools, the conversation is likely to shift from “Is estrogen too dangerous?” to “Which patients are best suited to an estrogen-based approach?”
For now, estradiol patches should be viewed as a rigorously tested, evidence-backed alternative to LHRH agonist injections for men with advanced prostate cancer. They offer comparable testosterone suppression and cardiovascular safety, with a distinct side-effect and logistical profile that may better align with the needs of some patients. As ongoing research clarifies their role alongside ARPIs and other systemic therapies, patches could move from experimental option to mainstream component of prostate cancer care, reshaping a cornerstone of treatment that has remained largely unchanged for decades.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
